Join MySLAS Social


SLAS: Committed to Shared Success

By Alan E. Fletcher, Ph.D.

Greetings to the remarkable SLAS community; it is my honor to serve as your 2019 president! Having just participated in SLAS2019, I was amazed at the knowledgeable, well-connected and multi-disciplinary assembly of professionals committed to the shared success of one another. Fundamental to our combined success is our ability to engage others with diverse perspectives and varied professional disciplines so that we can listen to and learn from each other. This has been key to SLAS since its founding and is at the forefront of SLAS plans for the year ahead.


Arkin, Datwani and Haas Named to SLAS Board of Directors

With amazing careers spanning all areas represented by the SLAS community, Michelle Arkin, Ph.D., Sammy Datwani, Ph.D. and Hansjoerg Haas, Ph.D., join the SLAS Board of Directors at SLAS2019. Along with six current SLAS Board members, Arkin, Datwani and Haas will further the SLAS mission to bring together researchers in academia, industry and government to advance life sciences discovery and technology via education, knowledge exchange and global community building.


Targeted Protein Degradation: The Power of PROTACs

Could hijacking one of the body’s own systems be the key to finding new targets for hard-to-treat diseases? Dane Mohl, Ph.D., scientist at Amgen (Thousand Oaks, CA) believes it may be. With the advent of genomics, drug development has focused on using genetics to identify therapeutic targets, which has led to targets that aren’t necessarily easily drugged through traditional methods. “Letting genetics guide our choices for treating disease means we have to use whatever modalities are available,” Mohl says. “We have to be more creative and that means we need a larger tool box to get to those new targets.”